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employment than non-smokers or ex-smokers: 14.26% of subjects acknowledge having 
had their employment disrupted within the past 6 months.The differences noted 
between the “smokers”, “ex smoker” and “non smoker” populations are statistically 
signiﬁcant (P < 0.001) with prevalence of disrupted employment respectively of 19%, 
15.25% and 11.57% (p < 0.01). It is also noted that the prevalence of smoking during 
work hours is signiﬁcantly more important when the hierarchical superior smokes. 
64.44% smoke during work hours if the hierarchical superior smokes, vs51.17% if the 
hierarchical superior does not smoke ( p < 0.004) CONCLUSIONS: In a population 
representative of persons at work on French soil, this study conﬁrms the data collected 
abroad and in certain businesses in France. Therefore, the justiﬁcation for taking 
smoking into account at the work place is reinforced by its health consequences as well 
as its direct consequences on the work produced.
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OBJECTIVES: Cow Milk Allergy (CMA) is estimated to occur in 5% of newborns in 
the USA. Ten states instated legislation that requires health coverage for amino acid 
formulas for CMA. This study aims at assessing the effects of this legislation on health 
care resource use and time to diagnosis for these states and to predict the effects for 
the whole country by extrapolating, should all states adopt similar legislation. Two 
scenarios may explain a better access to amino acid formulas in mandated states: 1) 
amino acid formulas are used as ﬁrst treatment option by specialists when patients 
have not reached symptom resolution at the community paediatrician level, or 2) all 
patients try a maximum of 2 treatment options, before amino acids are prescribed. 
METHODS: This study uses a decision analytical model with resource use data elicited 
from 202 health care professionals combined with probabilistic sensitivity analysis 
using a beta distribution with 20% standard deviation around the means to assess 
uncertainty of the input parameters. RESULTS: Health care resource use attributable 
to CMA treatment in the combined 50 states amounts to 371,043 community paedia-
trician visits, 3,695 hospital paediatrician visits, 17,704 outpatient paediatric gastro-
enterologist visits and 6,779 allergist visits. 6,216,006 days are spent to reach 
symptom resolution. The predicted reduction in number of total specialist visits for 
the USA for scenario 1 is 4,532, and 9,888 for scenario 2. The reduction in time to 
diagnosis amounts to 84,188 days for scenario 1 and 292,783 days for scenario 2. 
CONCLUSIONS: Legislation requiring coverage for amino acids after diagnosis of 
CMA is likely to reduce health care resource use in the USA, free up time of health 
care professionals to use in an alternative way, as well as reduce the time to diagnosis, 
which reduces the suffering of children with CMA.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes 
Studies
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OBJECTIVES: To assess the relationship between the daily dosing frequency (DDF) 
of COPD pharmacotherapies and treatment compliance; to estimate the effect of 
compliance on health care resource utilization (HCRU) and costs. METHODS: COPD 
patients were identiﬁed using a health insurance claims database covering 8 million 
lives (1999–2006). Patients were stratiﬁed based on the recommended DDF (QD, BID, 
TID, QID) of their ﬁrst COPD drug claim post COPD diagnosis. Compliance was 
measured using proportion of days covered (PDC). HCRU outcomes included inpa-
tient days and medical visits (inpatient, outpatient, and emergency room). A multivari-
ate regression model assessed the relationship between compliance and one-year 
HCRU controlling for demographics, comorbidities, and baseline resource use. Unit 
health care costs were obtained from the 2005 Medical Expenditure Panel Survey data 
and adjusted to 2008 dollars. Total costs were modeled by multiplying unit costs by 
the observed HCRU. RESULTS: Sample sizes ranged from 3,678 (QD) to 25,011 
(BID). Compliance was strongly correlated with DDF: PDC over one year for QD, 
BID, TID, and QID patients was 43%, 37%, 30%, and 23%, respectively (all p < 
0.001 vs. QD). Multivariate analysis showed that one-year compliance was correlated 
with HCRU. For 1,000 COPD patients, a 5 percentage point increase in PDC reduced 
the number of inpatient visits by 2.5%, hospital inpatient days by 3.1%, and emer-
gency room visits by 1.8%; the estimated number of outpatient visits increased by 
0.2% (p < 0.001 for all comparisons). This increase in compliance yielded approxi-
mately $300,000 in cost savings from decreased HCRU. CONCLUSIONS: COPD 
patients who initiated treatment with QD dosing had signiﬁcantly higher compliance 
than those with more frequent dosings. Patients with higher compliance were found 
to incur fewer hospital- and emergency room-related visits. In a hypothetical cohort 
of 1,000 COPD patients, increasing PDC by 5 percentage points would save $300,000 
per year, mostly from reduced hospital visits.
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OBJECTIVES: To analyze the effect of cost-sharing levels and other co-variates on 
adherence to asthma controller therapy among patients with moderate persistent 
asthma. METHODS: Data for this study came from a large administrative claims 
dataset (MarketScan). The selection criteria for this study included patients with at 
least one asthma-related outpatient claim (ICD-9-CM 493.XX).Asthma patients on 
dual controller therapy (ICS and LABA or ICS and LTRA) were identiﬁed and the 
initial date of LABA or LTRA prescription served as the index date.Patients were 
required to be continuously enrolled during the entire study period. The medication 
possession ratio (MPR) was used to measure adherence. RESULTS: A total of 1,447 
patients met the study criteria. Of these patients, 898 (62.1%) were initiated on 
ICS+LABA, and 549 (37.9%) were initiated on ICS+LTRA. The average combined 
adherence to controller regimen was 0.45 (median = 0.43) for the entire study popula-
tion.The odds of having increased adherence (MPR above the median) decreased 
signiﬁcantly with the increase in cost-sharing levels. Compared with patients having 
$0–15 cost-sharing level, patients having $16–30 (odds ratio [OR] = 0.449, 95% CI 
= 0.312–0.616 ), $31–45 (OR = 0.246, 95% CI = 0.168–0.358) and $46 and more 
(OR = 0.131, 95% CI = 0.084–0.206) had lower odds of having appropriate adher-
ence. Type of insurance plan, geographical region, and type of controller therapy were 
also signiﬁcantly associated with adherence. CONCLUSIONS: Even though the need 
to be adherent is greater among patients on dual-controller therapy, cost-sharing levels 
played an important role in level of adherence. The study also found the type of 
controller medication to be associated with the adherence to the therapy.
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OBJECTIVES: Translation and linguistic validation of patient reported outcomes 
(PRO) measures is an essential component of research methodology in preparation 
for multinational clinical trials. The EXAcerbations of Chronic Pulmonary Disease 
Tool (EXACT) was designed to evaluate frequency, severity, and duration of acute 
exacerbations of chronic obstructive pulmonary disease (COPD), including chronic 
bronchitis. The EXACT is 14-item daily diary designed to be administered on an 
electronic handheld device (e.g. personal digital assistant (PDA)). The objective of this 
work was to translate and linguistically validate the EXACT for use in 17 countries: 
Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Hungary, Japan, Korea, The 
Netherlands, Peru, Philippines, Poland, Romania, South Africa, Taiwan and UK. 
METHODS: The EXACT was translated according to industry standard methodol-
ogy, including detailed item deﬁnitions based on qualitative work conducted during 
instrument development. Five patients per country completed the respective translated 
questionnaire and participated in a cognitive interview. Interviews were conducted 
using a standardized guide to assess the understandability, cultural relevance, and 
appropriateness of wording of the translations. Qualitative analyses were performed 
to ensure that the content validity of the EXACT was maintained and equivalent 
across language versions. RESULTS: The study sample consisted of 90 patients with 
COPD (57.7% male). Mean age was 63 years. The sample consisted of patients who 
speak 14 languages collectively. All EXACT translations were well understood and 
proved relevant to the patients in this sample. Of interest, terms such as, “chest feel 
tight”, and “short of breath” were understood and described similarly by participants 
across countries. CONCLUSIONS: The results indicate the EXACT translations were 
conceptually equivalent to the English source version and easily understood by the 
target population for all 17 countries. We consider these translations acceptable for 
PRO assessment in international research and clinical trials, bringing the total number 
of validated EXACT translations to 25.
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OBJECTIVES: This study aimed to quantify the preferences of people with latent 
tuberculosis infection (LTBI) when making decisions on whether to accept preventive 
treatment with Isoniazid and to understand the trade-off nature of their decision-
making. METHODS: English-speaking adults with LTBI were recruited from the 
tuberculosis (TB) clinic at British Columbia Centre for Disease Control. A custom-
designed discrete choice experiment (DCE) measured preferences for 6 attributes of 
preventive treatment decision-making. A conditional logit model was performed to 
estimate respondents’ preferences. RESULTS: Among the 152 participants, 142 
(93.4%) with valid DCE responses were included for data analyses. Their average age 
